New York, New York 10016

  • Pre Diabetes

Purpose:

This study aims to understand the effects of automated physician directed messaging on patient engagement in the digital diabetes prevention program (dDPP). The messages are tailored to patient engagement levels based on established engagement thresholds, which are based on the patient's use of the dDPP application. The system is designed to minimize work for providers by sending automated targeted messages to patients to potentially increase engagement, prevent onset of diabetes and improve clinical outcomes. The patients in the study are automatically nudged using a combination of text messaging and MyChart messaging.


Study summary:

Using a mixed-methods design, this study will be completed in three phases. For Phase 3, we aim to conduct a randomized control trial with 400 patients with pre-diabetic, all of whom will be using the dDPP application. Half of enrolled patients will be randomized to the intervention group and receive automated targeted messaging.


Criteria:

Inclusion Criteria: - 18 years or older, BMI ≥ 25 kg/m2 (> 22 kg/m2 if self-identified as Asian) - Must be a NYU Langone patient - A diagnosis of prediabetes (either diagnosis of prediabetes or an HbA1C level of 5.7%-6.4% in past 12 months) or diabetes risk factors (BMI ≥ 25 kg/m2 or > 22 kg/m2 if self-identified as Asian - Safe to engage in moderate physical exercise (as determined by their PCP) - Sufficient English to be able to complete the enrollment process - Has app-capable device with data to use the dDPP application and receive text messages Exclusion Criteria: - Diagnosed with diabetes - Patients whose weight may vary considerably over the study's timeframe for reasons other than the intervention (e.g. cancer, pregnancy, ascites, severe CHF) - Patients with severe psychiatric disease or dementia - Active health condition that prevents them from engaging in moderate exercise


NCT ID:

NCT04773834


Primary Contact:

Principal Investigator
Devin Mann, MD
NYU Langone Health

Devin Mann, MD
Phone: 212-263-8313
Email: hibrid.lab@nyulangone.org


Backup Contact:

N/A


Location Contact:

New York, New York 10016
United States

Devin Mann, MD
Phone: 212-263-8313
Email: hibrid.lab@nyulangone.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 22, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.